* Hoffmann-La Roche Inc., of Nutley, N.J., and Japan-basedAjinomoto Co. extended their 1988 licensing agreement on the latter'sinterleukin-2 (IL-2) gene therapy and IL-2 fusion proteins. Under thenew agreement, Hoffmann-La Roche has rights to sell the technologyworldwide, except in Japan and other Asian countries where Ajinomotoretains those rights. In addition, Ajinomoto has exclusive rights tocommercialize its IL-2 fusion proteins that act as antagonists.* GENE-TRAK Inc., of Framingham, Mass., obtained rights from thePublic Health Research Institute, of New York, to develop the latter'sbinary probe technology in diagnostic assays. GENE-TRAK plans touse the technology with its Q-Beta amplified nucleic acid diagnosticproducts.* ARIAD Pharmaceuticals Inc., of Cambridge, Mass., said its publiclytraded units, which consist of one share of common stock and onewarrant, will no longer trade on the NASDAQ market, effective today.Instead, the common stock (ARIA) and warrants (ARIAW) will begintrading separately on NASDAQ. The warrants have an exercise price of$8.40 per share and expire May 20, 1999. ARIAD issued more than 2million warrants and an equal number of shares of common stockduring the company's initial public offering May 20.* Inflazyme Pharmaceuticals Ltd., of Vancouver, Canada, plans to raise$60,000 through the private placement of 100,000 shares at 60 centsper share. The placement also includes non-transferable share purchasewarrants for another 100,000 shares, exercisable for two years at 80cents per share.* Immunomedics Inc., of Morris Plains, N.J., and NeoRx Corp., ofSeattle, settled a patent infringement lawsuit. Under the terms, NeoRxgave Immunomedics a non-exclusive, royalty-free license to U.S.patent No. 4,877,868 for all of Immunomedics' imaging products, andImmunomedics gave NeoRx a non-exclusive, royalty-free license toU.S. patent 4,331,641 for certain NeoRx imaging products. No cashdamages were involved.
(c) 1997 American Health Consultants. All rights reserved.